Development of Carborane-Based Benzothiazole Analogues as Cannabinoid Receptor Type 2 (CB2R) Ligands

2Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The cannabinoid receptor type 2 (CB2R) is upregulated in the brain under pathological conditions. To distinguish between the healthy and disease states, Positron Emission Tomography (PET), as a noninvasive imaging technique, is employed, for which suitable highly affine and selective CB2R radioligands are required. The benzothiazole scaffold is a promising core structure that has been modified with different substituents. Recently, we have reported naphthyridinone- and thiazole-based carborane-substituted CB2R ligands and investigated the first carborane-based CB2R radiotracer [18F]LUZ5-d8in preliminary biological tests. Carboranes are cluster compounds that are used as hydrophobic surrogates in drug design. We here report the synthesis, characterization, binding affinity data and docking results of three promising isomeric carborane-substituted benzothiazole-based CB2R ligands. The ortho-, meta- and para-carborane derivatives exhibit a nanomolar affinity and high selectivity toward CB2R, with the meta-carborane derivative being the most affine compound experimentally and in docking studies.

Cite

CITATION STYLE

APA

Ueberham, L., Kazimir, A., Deuther-Conrad, W., & Hey-Hawkins, E. (2025). Development of Carborane-Based Benzothiazole Analogues as Cannabinoid Receptor Type 2 (CB2R) Ligands. ACS Omega, 10(33), 38264–38271. https://doi.org/10.1021/acsomega.5c06508

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free